Synthetic Biologics Stock

Synthetic Biologics Inc. The Company’s lead candidates poised for Phase 3 improvement are: (1) SYN-004 (ribaxamase) which is designed to shield the gut microbiome from the effects of certain generally made use of intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to decrease the impact of methane producing organisms in the gut microbiome to treat an underlying result in of irritable bowel syndrome with constipation (IBS-C).

GuruFocus has detected two Warning Indicators with Synthetic Biologics Inc SYN. See Synthetic Biologics’ periodic filings with the Securities and Exchange Commission for extra full facts. Synthetic Biologics Inc. Under, we examine the compound annual growth forbes welcome price — CAGR for quick — of an investment into Synthetic Biologics shares, beginning with a $ten,000 acquire of SYN, presented on a split-history-adjusted basis factoring in the full Synthetic Biologics stock split history.Synthetic Biologics Stock

Synthetic Biologics is a clinical corporation focused on developing therapeutics made to maintain the microbiome. According to our Synthetic Biologics stock split history records, Synthetic Biologics has had splits. (NYSE MKT: SYN) is a late-stage clinical organization creating therapeutics that preserve the microbiome to safeguard and restore the overall health of sufferers. New videos are added nearly every day to the Stock News Now channel sharing fascinating stories and companies from the MicroCap stock market.

The Company’s lead candidates poised for Phase three improvement are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain generally employed intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (two how to write your essay in half the time) SYN-010 which is intended to lessen the influence of methane producing organisms in the gut microbiome to treat an underlying bring about of irritable bowel syndrome with constipation (IBS-C).

SNNLive spoke with Jeff Riley, CEO of Synthetic Biologics, Inc.

Synthetic Biologics Inc. Synthetic Biologics is a clinical corporation focused on establishing therapeutics made to maintain the microbiome. According to our Synthetic Biologics stock split history records, Synthetic Biologics has had splits. (NYSE MKT: SYN) is a late-stage clinical firm developing therapeutics that preserve the microbiome to protect and restore the wellness of individuals. New videos are added practically every single day to the Stock News Now channel sharing fascinating stories and companies from the MicroCap stock market.

The Company’s lead candidates poised for Phase three improvement are: (1) SYN-004 (ribaxamase) which is created to guard the gut microbiome from the effects of certain frequently employed intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (two) SYN-010 which is intended to lower the impact of methane generating organisms in the gut microbiome to treat an underlying bring about of irritable bowel syndrome with constipation (IBS-C).

Synthetic Biologics, Inc. A preliminary prospectus supplement and the accompanying prospectus relating to these securities have been filed with the SEC and are readily available at the SEC’s web-site at Ahead of investing, you ought to study the preliminary prospectus supplement and the accompanying prospectus for info about Synthetic Biologics and this providing. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics focused on the gut microbiome.

(NYSE MKT: SYN) is a late-stage clinical business creating therapeutics focused on the gut microbiome. The interview could include forward-seeking statements about Synthetic Biologics, Inc.

Leave a Reply